AKT1 and cancer: Consistent with these findings, exogenous IL-15 did not affect cancer cell-intrinsic IL-15-mediated activation of the AKT-mTORC1pathway (Fig. 8C), but its effect on reducing RhoA activity and the phosphorylation of MLC2 and FAK was not affected (Fig. 8D).